Serotonin, Psilocybin, and Body Dysmorphic Disorder

Study at a glance

Characteristics	Open-label pilot study Peer reviewed
Sample size	8
Population	Adults with body dysmorphic disorder
Topics	Psilocybin Serotonin
Keywords	Body dysmorphic disorder Hallucinogen
Citations	52
Key points	Psilocybin-assisted psychotherapy produced clinically meaningful reductions in BDD symptom severity that were maintained at 3-month follow-up.

Cognitive Neuropsychiatry Research Unit, Mental Health Research Institute, Parkville, Victoria, Australia.

Other non-randomized and open-label trials on serotonin, most cited first.

Study	Year	Design	Participants
Serotonin 2A Receptor Agonist Binding in the Human Brain with [11C]Cimbi-36 Healthy volunteers	2014	First-in-human clinical trial	n = 29
Localization of serotonin 5‐HT2 receptors in living human brain by positron emission tomography using N1‐([11C]‐methyl)‐2‐BR‐LSD Normal human volunteers	1987	Clinical trial	n = 7
Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder. Adults with moderate-to-severe non-delusional body dysmorphic disorder unresponsive to...	2023	Open-label trial	n = 12
Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings Patients with treatment-resistant depression receiving serial intravenous ketamine...	2023	Retrospective review of clinical trial data with literature search	n = 26
Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression Patients with major depressive disorder	2024	Post hoc exploratory analysis of a clinical trial

and 14 more in the library